Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes

British Journal of Clinical Pharmacology

Volumn 44, Issue 5, 1997, Pages 505-511

  Zhao, Xue Jun ^a   Ishizaki, Takashi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

3 Hydroxylation; Antimalarials; CYP3A4; Drug interaction; Human liver microsomes; Quinine

Indexed keywords

3 HYDROXYQUININE; ANTIMALARIAL AGENT; ATOVAQUONE; CHLOROQUINE; CIMETIDINE; CYCLOGUANIL; CYTOCHROME P450 ISOENZYME; DAPSONE; DIAZEPAM; DILTIAZEM; DOXYCYCLINE; ERYTHROMYCIN; HALOFANTRINE; HYDRALAZINE; KETOCONAZOLE; LIDOCAINE; MEFLOQUINE; NIFEDIPINE; NORFLOXACIN; OLEANDOMYCIN; OMEPRAZOLE; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; QUINIDINE; QUININE; TETRACYCLINE; TROLEANDOMYCIN; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL;

EID: 0030665573     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.t01-1-00619.x     Document Type: Article

References (52)

1. Tracy JW, Webster LT. Drugs used in the chemotherapy of protozoal infections. Malaria. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, eds Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, New York: McGraw-Hill, 1996, pp. 965-985.
2. Moran JS, Bernard KW. The spread of chloroquine-resistant malaria in Africa. Implication for travelers. JAMA 1989; 262: 245-248.
3. Wernsdorfer WH. The development and spread of drug-resistant malaria. Parasitol Today 1991; 7: 297-303.
4. Bradley D. Prophylaxis against malaria for travellers from the United Kingdom. Br Med J 1993; 306: 1247-1252.
5. White NJ. Drug treatment and prevention of malaria. Eur J Clin Pharmacol 1988; 34: 1-14.
6. White NJ. Antimalarial pharmacokinetics and treatment regimens. Br J Clin Pharmacol 1992; 34: 1-10.
7. Hien TT, White NJ. Qinghaosu. Lancet 1993; 341: 603-608.
8. Boele van Hensbroek M, Onyiorah E, Jaffar S, et al. A trial of artemether or quinine in children with cerebral malaria. N Engl J Med 1996; 335: 69-75.
9. Hien TT, Day NPJ, Phu NH, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335: 76-83.
10. Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clin Pharmacokinet 1996; 30: 263-299.
11. Wanwimolruk S, Wong SM, Zhang H, Coville PF, Walker RJ. Metabolism of quinine in man: identification of a major metabolite, and effects of smoking and rifampicin pretreatment. J Pharm Pharmacol 1995; 47: 957-963.
12. Wanwimolruk S, Wong SM, Zhang H, Coville PF. Simultaneous determination of quinine and a major metabolite 3-hydroxyquinine in biological fluids by HPLC without extraction. J Lig Chromatogr 1996; 19: 293-305.
13. Zhao X-J, Yokoyama H, Chiba K, Wanwimolruk S, Ishizaki T. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human liver microsomes and nine recombinant human cytochromes P450. J Pharmacol Exp Ther 1996; 279: 1327-1334.
14. Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S. Metabolism of quinine in humans: evidence for the involvement of human CYP3A in the hepatic metabolism of quinine. Br J Clin Pharmacol 1997; 43: 245-252.
15. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Critical Rev Toxicol 1992; 22: 1-21.
16. Brockmöller J, Roots I. Assessment of liver metabolic function: clinical implications, Clin Pharmacokinet 1994; 27: 216-248.
17. Andersson J. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9-28.
18. Panisko DM, Keystone JS. Treatment of malaria - 1990. Drugs 1990; 39: 160-189.
19. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 1993; 266: 52-59.
20. Echizen H, Kawasaki H, Chiba K, Tani M, Ishizaki T. A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-deakylation metabolism of disopyramide with human liver microsomes. J Pharmacol Exp Ther 1993; 264: 1425-1431.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
22. Shanks GD, Edstein MD, Surigamongkol V, Jimaad S, Webster HK. Malaria chemoprophylaxis using proguanil/dapsone combinations on the Thai-Cambodian border. Am J Trop Med Hyg 1992; 46: 643-648.
23. Sarma PS. Norfloxacin: a new drug in the treatment of falciparum malaria. Ann Int Med 1989; 111: 336-337.
24. Carrington HC, Crother AF, Davey DG, Levi AA, Rose TL. A metabolite of Paludrine with high antimalarial activity. Nature 1951; 168: 1080.
25. Watkins WM, Sixsmith DG, Chulay JD. The activity of proguanil, cycloguanil and p-chlorophenylbiguanide against Plasmodium falciparum in vitro. Ann Trop Med Parasitol 1984; 78: 273-278.
26. Martin SK, Odnola AMJ, Milhous WK. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 1987; 235: 899-901.
27. Beedham C, Al-Tayib Y, Smith JA. Role of guinea pig and rabbit hepatic aldehyde oxidise in oxidative in vitro metabolism of cinchona antimalarials. Drug Metab Dispos 1992; 26: 889-895.
28. Guengerich FP, Müller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 1986; 30: 287-295.
29. Watkins PB, Wrighton SA, Maure JP, et al. Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci (USA) 1985; 82: 6310-6314.
30. Chang T, Gonzalez F, Waxman D. Evaluation of triacetyloleandomycin. α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 1994; 311: 437-442.
31. Verapamil: pp. V 12-V18, nifedipine: pp. N80-N87 and primaquine: pp. P209-P218, In Therapeutic drugs, eds Dollery SCTC, Boobis AR, Burley D, et al., London: Churchill Livingston, 1991.
32. Verapamil: pp. V 12-V18, nifedipine: pp. N80-N87 and primaquine: pp. P209-P218, In Therapeutic drugs, eds Dollery SCTC, Boobis AR, Burley D, et al., London: Churchill Livingston, 1991.
33. Verapamil: pp. V 12-V18, nifedipine: pp. N80-N87 and primaquine: pp. P209-P218, In Therapeutic drugs, eds Dollery SCTC, Boobis AR, Burley D, et al., London: Churchill Livingston, 1991.
34. Kapusnik-Uner JE, Sande MA, Chambers HF. Antimicrobial agents. Tetracyclines. chloramphenicol, erythromycin, and miscellaneous antibacterial agents. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, eds Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, New York: McGraw-Hill, 1996, pp. 1123-1153.
35. Karbwang J, Na Bangchang K, Thanavibul A, Wattanakoon Y, Harinasuta T. Quinine toxicity when given with doxycycline and mefloquine. Southeast Asian J Trop Med Public Health 1994; 25: 397-400.
36. Couet W, Laroche R, Floch JJ, Istin B, Fourtillan JB, Sauniere JF. Pharmacokinetics of quinine and doxycycline in patients with acute falciparum malaria: A study in Africa. Ther Drug Monit 1991; 13: 496-501.
37. Andersson T, Miners JO, Veronese ME, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36: 521-530.
38. Andersson T, Miners JO, Veronese ME, Birkett DJ. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP 3A isoforms. Br J Clin Pharmacol 1994; 38: 131-137.
39. Na Bangchang K, Karbwang J, Back DJ. Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem Pharmacol 1992; 44: 587-590.
40. Maurice M, Pichard L, Daujat M, et al. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 1992; 6: 752-758.
41. Back DJ, Tjia JF, Karbwang J, Colbert J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharmacol 1988; 26: 23-29.
42. Back DJ, Stevenson P, Tjia JF. Comparative effects of two antimycotic agents, ketoconazole and terbinafine, on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br J Clin Pharmacol 1989; 28: 166-170.
43. Eugster HP, Sengstag C. Saccharomyces cerevisae: an alternative source for human liver microsomal enzymes and its use in drug interaction studies. Toxicology 1993; 82: 61-73.
44. Bourrie M, Meunier V, Berger Y, Fabre G. Cytochrome P450 isoform inhibitions as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 1996; 277: 321-332.
45. Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-158.
46. Shimada J, Yamazaki H, Miura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
47. Christians U, Schmidt G, Bader A, et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol 1996; 41: 187-190.
48. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996; 277: 805-816.
49. Schwab GE, Rancy JR, Johnson EF. Modulation of rabbit and human hepatic cytochrome P450 catalyzed steroid hydroxylation by α-naphthoflavone. Mol Pharmacol 1988; 33: 493-499.
50. Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC. Beaune P. Involvement of cytochrome P4503A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol 1994; 47: 1883-1895.
51. Yun CH, Wood M, Guengerich FP. Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P4503A. Anesthesiology 1992; 77: 467-474.
52. Irshaid Y, Branch RA, Adedoyin A. Metabolic interactions of putative cytochrome P4503A substrates with alternative pathways of dapsone metabolism in human liver microsomes. Drug Metab Dispos 1996; 24: 164-171.